Eli Lilly (Singapore)

Recent papers from Eli Lilly (Singapore)

1. A Review of Semi‐Mechanistic HbA1c Models in People with Type 2 Diabetes: Strengths, Limitations, and ApplicationsThe Journal of Clinical Pharmacology · 2026
2. Advancing cell and gene therapy: Application of AI/ML in clinical development and patient managementJournal of Biopharmaceutical Statistics · 2026
3. Evaluation of Machine Learning Approaches for Estimating Individualized Treatment Regimens for Time-to-Event Outcomes in Observational StudiesStatistics in Biopharmaceutical Research · 2025
4. Essential Role for Trf2 in Cardiac Development and Function2025
5. Spontaneous peripheral oxygen desaturation and apnea events in mice vary by strain and inspired oxygen level2025
6. A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small MoleculesCPT Pharmacometrics & Systems Pharmacology · 2025
7. Mirikizumab Pharmacokinetics and Exposure-Response in Patients With Moderately-To-Severely Active Crohn's Disease: Results From Two Randomized Studies.2025
8. Sensitivity Analysis for Unmeasured Confounding in Medical Product Development and Evaluation Using Real World EvidenceStatistics in Biopharmaceutical Research · 2025
9. Evaluation of Four Semi‐Mechanistic Models for Predicting Glycemic Control With a Glucagon Receptor Antagonist in People With Type 2 DiabetesCPT Pharmacometrics & Systems Pharmacology · 2025
10. Impact of Lipoprotein(a) on Valvular and Cardiovascular Outcomes in Patients With Calcific Aortic Valve StenosisJournal of the American Heart Association · 2025
11. IFN-α Induces Heterogenous ROS Production in Human β-Cells2025
12. Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitisCPT Pharmacometrics & Systems Pharmacology · 2024
13. Beyond the Screen: Exploring Digital Health Experiences of Individuals Affected by Psoriasis – A Qualitative Interview Study2024
14. Mirikizumab Exposure–Response Relationships in Patients with Moderately‐to‐Severely Active Ulcerative Colitis in Randomized Phase II and III StudiesClinical Pharmacology & Therapeutics · 2024
15. Clinical Relevance of Donanemab Treatment (S1.004)Neurology · 2024
16. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung CancerJTO Clinical and Research Reports · 2024
17. Twelve-month analysis of real-world evidence from a commercial telehealth obesity treatment provider2024
18. Early Cardio-Oncology Intervention in Thoracic Radiotherapy: Results of the Cardiac Aggressive Risk Mitigation (CARMA) Pilot Study2024
19. Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RABMJ Open · 2024
20. Racial and ethnic differences in the degree of participation and retention in a decentralized cohort study of COVID-19 immunization in patients with inflammatory bowel diseasesJournal of Clinical and Translational Science · 2024